Sanofi S.A. and GlaxoSmithKline (GSK) plc announced on Wednesday that they have reached an agreement with the United Kingdom's government for the supply of up to 60 million doses of a coronavirus vaccine, APA reports citing Teletrader.
"With our partner GSK, we are pleased to cooperate with the UK government as well as several other countries and global organizations as part of our ongoing efforts to develop a safe and effective vaccine and make it available as quickly as possible. We greatly appreciate the UK government's support of this shared vision," Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, noted in a press release.
French pharmaceutical firm also said it expects that a Phase 1/2 trials would begin in September, with a Phase 3 study that would ensue by the end of the year. "Regulatory approval could be achieved by the first half of 2021" if the testing shows that the vaccine is successful at COVID-19 prevention, Sanofi specified.